MDT

86.26

-0.28%↓

114.89

-0.48%↓

VEEV

174.73

+0.5%↑

HQY

83.39

-1.43%↓

PHR.US

9.05

+8.51%↑

MDT

86.26

-0.28%↓

114.89

-0.48%↓

VEEV

174.73

+0.5%↑

HQY

83.39

-1.43%↓

PHR.US

9.05

+8.51%↑

MDT

86.26

-0.28%↓

114.89

-0.48%↓

VEEV

174.73

+0.5%↑

HQY

83.39

-1.43%↓

PHR.US

9.05

+8.51%↑

MDT

86.26

-0.28%↓

114.89

-0.48%↓

VEEV

174.73

+0.5%↑

HQY

83.39

-1.43%↓

PHR.US

9.05

+8.51%↑

MDT

86.26

-0.28%↓

114.89

-0.48%↓

VEEV

174.73

+0.5%↑

HQY

83.39

-1.43%↓

PHR.US

9.05

+8.51%↑

Home・Akciju saraksts・Intra-Cellular Therapies Inc

Intra-Cellular Therapies Inc

Slēgts

SektorsVeselības aprūpe

Pirkt Pārdot

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

Max

Rekomendācijas
By TipRanks
Rekomendācijas	Pirkt
Prognoze 12 mēnešiem	-0.79% downside

Ziņu noskaņojums

By Acuity

100%

333 / 349 Rangs Healthcare

Tehniskais rādītājs

By Trading Central

Pārliecība

Weak Bullish Evidence

131.5 / 131.92 Atbalsts un pretestība

Intra-Cellular Therapies Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 6. apr. 23:17 UTC

Peļņas

Samsung Forecasts Record First-Quarter Operating Profit

2026. g. 6. apr. 23:00 UTC

Karstas akcijas

Stocks to Watch: Health Insurers, Mawson, Owlet

2026. g. 6. apr. 22:13 UTC

Galvenie tirgus virzītāji

Health Insurance Shares Gain on 2.48% Medicare Rate Bump

2026. g. 6. apr. 21:46 UTC

Iegādes, apvienošanās, pārņemšana

BP 'Optimizes Portfolio' and Sells 13 Thorntons Stores to Giant Oil -- OPIS

2026. g. 6. apr. 17:09 UTC

Galvenie tirgus virzītāji

Viridian Shares Fall After Competing Amgen Eye Drug Performs Well

2026. g. 6. apr. 16:56 UTC

Galvenie ziņu notikumi

U.S. Released 1.5 Million Bbls of Crude From SPR Last Week, DOE Data Show -- OPIS

2026. g. 6. apr. 14:47 UTC

Galvenie tirgus virzītāji

Stereotaxis Shares Rise on FDA Clearance for Synchrony

2026. g. 7. apr. 00:00 UTC

Galvenie ziņu notikumi

Ukraine's Lesson for Trump: Military Dominance Opens Waterways -- WSJ

2026. g. 6. apr. 23:58 UTC

Tirgus saruna

Galvenie ziņu notikumi

Iran War Will Keep Oil Prices High Through 2Q, Says Westpac -- Market Talk

2026. g. 6. apr. 23:50 UTC

Tirgus saruna

Nikkei May Rise on Hopes for Iran Cease-Fire -- Market Talk

2026. g. 6. apr. 23:36 UTC

Tirgus saruna

Gold Edges Higher as Investors Focus on U.S.-Iran Conflict -- Market Talk

2026. g. 6. apr. 23:15 UTC

Tirgus saruna

RBA Won't Raise Rates as Australia's Economy Softens Fast -- Market Talk

2026. g. 6. apr. 22:52 UTC

Tirgus saruna

Global Equities Roundup: Market Talk

2026. g. 6. apr. 22:52 UTC

Tirgus saruna

Pro Medicus Unlikely to Complete New Buyback in Full -- Market Talk

2026. g. 6. apr. 22:14 UTC

Tirgus saruna

Correction to Live Cattle Futures Article

2026. g. 6. apr. 20:56 UTC

Tirgus saruna

Mexican Private Consumption Fell in January -- Market Talk

2026. g. 6. apr. 20:50 UTC

Tirgus saruna

Energy & Utilities Roundup: Market Talk

2026. g. 6. apr. 20:15 UTC

Tirgus saruna

Global Commodities Roundup: Market Talk

2026. g. 6. apr. 19:58 UTC

Tirgus saruna

Global Forex and Fixed Income Roundup: Market Talk

2026. g. 6. apr. 19:58 UTC

Tirgus saruna

Live Cattle Futures Hit Record High, Hogs Edge Up -- Market Talk

2026. g. 6. apr. 19:11 UTC

Tirgus saruna

U.S. Natural Gas Edges Up in Rangebound Trade -- Market Talk

2026. g. 6. apr. 19:06 UTC

Tirgus saruna

Treasury Yields Decline as a Belligerent Trump Talks to Reporters -- Market Talk

2026. g. 6. apr. 19:03 UTC

Tirgus saruna

Global Energy Roundup: Market Talk

2026. g. 6. apr. 19:03 UTC

Tirgus saruna

Crude Futures Edge Up As Trump's Iran Deadline Nears -- Market Talk

2026. g. 6. apr. 18:36 UTC

Iegādes, apvienošanās, pārņemšana

Soleno Stock Soars 32% on $2.9 Billion Neurocrine Buyout. Why Its Hunger Drug Is a Different Weight-Loss Play. -- Barrons.com

2026. g. 6. apr. 17:59 UTC

Tirgus saruna

Galvenie ziņu notikumi

Travel Booking Companies Facing More Demand Uncertainty Than Expected -- Market Talk

2026. g. 6. apr. 17:13 UTC

Iegādes, apvienošanās, pārņemšana

Soleno Stock Soars 32% on $2.9 Billion Neurocrine Buyout. Why Its Hunger Drug Is a Different Weight-Loss Play. -- Barrons.com

2026. g. 6. apr. 16:33 UTC

Tirgus saruna

Oil Futures Steady as Market Awaits Trump -- Market Talk

2026. g. 6. apr. 16:20 UTC

Tirgus saruna

Basic Materials Roundup: Market Talk

2026. g. 6. apr. 14:59 UTC

Peļņas

Strategy Records a $14.5 Billion Unrealized Loss in First Quarter -- WSJ

Salīdzinājums

Cenas izmaiņa

Intra-Cellular Therapies Inc Prognoze

Cenas mērķis

By TipRanks

-0.79% uz leju

Prognoze 12 mēnešiem

Vidējais 130.83 USD -0.79%

Augstākais 132 USD

Zemākais 118 USD

Pamatojoties uz 13 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Intra-Cellular Therapies Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt

13 ratings

Pirkt

Turēt

Pārdot

Pamatojoties uz 13 analītiķiem, kas pēdējo 3 mēnešu laikā snieguši akciju vērtējumus instrumentam Intra-Cellular Therapies Inc — pēdējo 3 mēnešu laikā.

Tehniskais rādītājs

By Trading Central

131.5 / 131.92Atbalsts un pretestība

There is one bullish event.

There are no events.

Noskaņojums

By Acuity

333 / 349 Rangs Veselības aprūpe

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

Par Intra-Cellular Therapies Inc

Intra-Cellular Therapies, Inc., a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States. The company offers CAPLYTA for the treatment of schizophrenia and bipolar depression in adults. It is also involved in developing Lumateperone, which is in Phase 3 clinical trial for the treatment of various depressive disorders, as well as additional neuropsychiatric indications. In addition, the company is developing Lenrispodun (ITI-214) for the treatment of Parkinson's disease, CNS, and other disorders; ITI-1284 for the treatment of neuropsychiatric disorders and behavioral disturbances in dementia; and ITI-333 for substance use disorders, pain, and psychiatric comorbidities, including depression, anxiety, and sleep disorders. Intra-Cellular Therapies, Inc. was founded in 2002 and is headquartered in New York, New York.